OGEN (Oragenics) Non Operating Income: $-0.02 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OGEN Oragenics Inc OGEN
30 GF Score
Price $0.50
! 1 Warning Sign
View Full Analysis

What is Oragenics Non Operating Income?

Oragenics OGEN +2.00% 30 Non Operating Income is $-0.02 Mil as of Mar. 2026. GuruFocus rates OGEN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Oragenics's Non Operating Income for the three months ended in Mar. 2026 was $-0.01 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02 Mil.

Oragenics Non Operating Income Related Terms

Oragenics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Oragenics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oragenics Non Operating Income Chart

Oragenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.07 -0.03 -0.01

Oragenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 -0.01 -0.01
OGEN
30GF Score
Oragenics Inc OGEN
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oragenics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-0.02 Mil mean?
Oragenics (OGEN) has a Non Operating Income of $-0.02 Mil as of Mar. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Oragenics and its competitors.
Is Oragenics' Non Operating Income too high?
Oragenics' current Non Operating Income is $-0.02 Mil. Overall, Oragenics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Oragenics' Non Operating Income compare to CMND and SLXN?
Oragenics' Non Operating Income of $-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Oragenics and its competitors. Oragenics's current Non Operating Income is $-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oragenics stock overvalued right now?
Oragenics (OGEN) has a current Non Operating Income of $-0.02 Mil. The current Non Operating Income is $-0.02 Mil. Oragenics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Oragenics (OGEN), the current Non Operating Income is $-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oragenics Business Description

Address 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL, USA, 34202
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score

Get the complete analysis for OGEN

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price